{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:12:40Z","timestamp":1772856760188,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.urology.2017.05.041","type":"journal-article","created":{"date-parts":[[2017,6,2]],"date-time":"2017-06-02T06:15:16Z","timestamp":1496384116000},"page":"271.e1-271.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The Beneficial Effect of Fesoterodine, a Competitive Muscarinic Receptor Antagonist on Erectile Dysfunction in Streptozotocin-induced Diabetic Rats"],"prefix":"10.1016","volume":"107","author":[{"given":"Didem","family":"Yilmaz-Oral","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nur","family":"Bayatli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serap","family":"Gur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2017.05.041_bib0010","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/nau.22582","article-title":"Pathophysiology of idiopathic overactive bladder and the success of treatment: a systematic review from ICI-RS 2013","volume":"33","author":"Hanna-Mitchell","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2017.05.041_bib0015","first-page":"130","article-title":"Economic burden of urgency urinary incontinence in the United States: a systematic review","volume":"20","author":"Coyne","year":"2014","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.urology.2017.05.041_bib0020","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"key":"10.1016\/j.urology.2017.05.041_bib0025","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.juro.2012.09.079","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline","volume":"188","author":"Gormley","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2017.05.041_bib0030","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1464-410X.2008.08036.x","article-title":"The economic impact of overactive bladder syndrome in six Western countries","volume":"103","author":"Irwin","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2017.05.041_bib0035","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1464-410X.2007.07205.x","article-title":"Muscarinic receptor antagonists for overactive bladder","volume":"100","author":"Abrams","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2017.05.041_bib0040","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11255-013-0551-7","article-title":"Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia: a prospective, randomized, multicenter study","volume":"46","author":"Lee","year":"2014","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.urology.2017.05.041_bib0045","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/j.1464-410X.2008.07761.x","article-title":"Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score","volume":"102","author":"Kaplan","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2017.05.041_bib0050","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/nau.20404","article-title":"Overactive bladder in diabetes: a peripheral or central mechanism?","volume":"26","author":"Yamaguchi","year":"2007","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2017.05.041_bib0055","doi-asserted-by":"crossref","first-page":"608","DOI":"10.4111\/kju.2014.55.9.608","article-title":"Effect of improvement in lower urinary tract symptoms on sexual function in men: tamsulosin monotherapy vs. combination therapy of tamsulosin and solifenacin","volume":"55","author":"Ko","year":"2014","journal-title":"Korean J Urol"},{"key":"10.1016\/j.urology.2017.05.041_bib0060","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00115-014-4127-2","article-title":"Diabetic neuropathy: do not only consider distal symmetrical neuropathy","volume":"86","author":"Doppler","year":"2015","journal-title":"Nervenarzt"},{"issue":"suppl 3","key":"10.1016\/j.urology.2017.05.041_bib0065","first-page":"55","article-title":"Guidelines for diagnosis and outpatient management of diabetic peripheral neuropathy. European Association for the Study of Diabetes, Neurodiab","volume":"24","author":"Boulton","year":"1998","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.urology.2017.05.041_bib0070","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.urology.2011.05.017","article-title":"Prevalence of overactive bladder and associated risk factors in 1359 patients with type 2 diabetes","volume":"78","author":"Liu","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.urology.2017.05.041_bib0075","doi-asserted-by":"crossref","first-page":"232","DOI":"10.5213\/inj.1632508.254","article-title":"Association between overactive bladder and polyneuropathy in diabetic patients","volume":"20","author":"Tanik","year":"2016","journal-title":"Int Neurourol J"},{"key":"10.1016\/j.urology.2017.05.041_bib0080","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00345-013-1175-3","article-title":"Overactive bladder in diabetes mellitus patients: a questionnaire-based observational investigation","volume":"32","author":"Palleschi","year":"2014","journal-title":"World J Urol"},{"key":"10.1016\/j.urology.2017.05.041_bib0085","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1507\/endocrj.EJ15-0237","article-title":"Prevalence of overactive bladder and its related factors in Japanese patients with diabetes mellitus","volume":"62","author":"Ikeda","year":"2015","journal-title":"Endocr J"},{"key":"10.1016\/j.urology.2017.05.041_bib0090","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1464-410X.2005.05392.x","article-title":"Recent advances in understanding the biology of diabetes-associated bladder complications and novel therapy","volume":"95","author":"Yoshimura","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2017.05.041_bib0095","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1016\/j.juro.2007.08.033","article-title":"Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome","volume":"178","author":"Nitti","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2017.05.041_bib0100","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1185\/03007995.2011.565044","article-title":"Effect of fesoterodine 4\u2009mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder","volume":"27","author":"Corcos","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.urology.2017.05.041_bib0105","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1464-410X.2008.07710.x","article-title":"Impact of fesoterodine on quality of life: pooled data from two randomized trials","volume":"102","author":"Kelleher","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2017.05.041_bib0110","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2490-11-9","article-title":"Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model","volume":"11","author":"Arlandis-Guzman","year":"2011","journal-title":"BMC Urol"},{"key":"10.1016\/j.urology.2017.05.041_bib0115","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.eururo.2006.04.018","article-title":"The current and future burden and cost of overactive bladder in five European countries","volume":"50","author":"Reeves","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2017.05.041_bib0120","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40266-014-0237-6","article-title":"Review of the efficacy and safety of fesoterodine for treating overactive bladder and urgency urinary incontinence in elderly patients","volume":"32","author":"Wagg","year":"2015","journal-title":"Drugs Aging"},{"key":"10.1016\/j.urology.2017.05.041_bib0125","first-page":"1559","article-title":"Efficacy of tadalafil once daily versus fesoterodine in the treatment of overactive bladder in older patients","volume":"19","author":"Dell'Atti","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.urology.2017.05.041_bib0130","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/ijir.2016.34","article-title":"Pomegranate juice causes a partial improvement through lowering oxidative stress for erectile dysfunction in streptozotocin-diabetic rat","volume":"28","author":"Onal","year":"2016","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.urology.2017.05.041_bib0135","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1016\/j.urology.2013.10.021","article-title":"The effect of intracavernosal avanafil, a newer phosphodiesterase-5 inhibitor, on neonatal type 2 diabetic rats with erectile dysfunction","volume":"83","author":"Yilmaz","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.urology.2017.05.041_bib0140","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/j.1464-410X.2007.07358.x","article-title":"Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo","volume":"101","author":"Ney","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2017.05.041_bib0145","doi-asserted-by":"crossref","first-page":"R108","DOI":"10.1152\/ajpregu.00033.2013","article-title":"Bladder and erectile dysfunctions in the type 2 diabetic Goto-Kakizaki rat","volume":"306","author":"Oger-Roussel","year":"2014","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.urology.2017.05.041_bib0150","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/bph.12143","article-title":"Ca2+-activated K+ channel (KCa) stimulation improves relaxant capacity of PDE5 inhibitors in human penile arteries and recovers the reduced efficacy of PDE5 inhibition in diabetic erectile dysfunction","volume":"169","author":"Gonzalez-Corrochano","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.urology.2017.05.041_bib0155","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/sj.ijir.3901054","article-title":"Effect of combination endothelial nitric oxide synthase gene therapy and sildenafil on erectile function in diabetic rats","volume":"16","author":"Bivalacqua","year":"2004","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.urology.2017.05.041_bib0160","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/bju.13515","article-title":"Mirabegron causes relaxation of human and rat corpus cavernosum: could it be a potential therapy for erectile dysfunction?","volume":"118","author":"Gur","year":"2016","journal-title":"BJU Int"},{"issue":"suppl 1","key":"10.1016\/j.urology.2017.05.041_bib0165","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000052266","article-title":"The importance of the cholinergic system in neurourology","volume":"34","author":"Andersson","year":"1998","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2017.05.041_bib0170","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0031-6997(25)06957-1","article-title":"Muscarinic receptor subtypes and smooth muscle function","volume":"48","author":"Eglen","year":"1996","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.urology.2017.05.041_bib0175","first-page":"159","article-title":"Expression of functional muscarinic acetylcholine receptor subtypes in human corpus cavernosum and in cultured smooth muscle cells","volume":"5","author":"Traish","year":"1995","journal-title":"Receptor"},{"key":"10.1016\/j.urology.2017.05.041_bib0180","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0022-3565(24)38739-7","article-title":"The biochemical and neurologic basis for the treatment of male erectile dysfunction","volume":"296","author":"Moreland","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.urology.2017.05.041_bib0185","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0022-5347(17)39653-2","article-title":"Characterization of muscarinic acetylcholine receptors in human penile corpus cavernosum: studies on whole tissue and cultured endothelium","volume":"144","author":"Traish","year":"1990","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2017.05.041_bib0190","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.phrs.2007.05.008","article-title":"Different responses to angiotensin-(1-7) in young, aged and diabetic rabbit corpus cavernosum","volume":"56","author":"Yousif","year":"2007","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.urology.2017.05.041_bib0195","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1600-0773.1997.tb02064.x","article-title":"Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine","volume":"81","author":"Nilvebrant","year":"1997","journal-title":"Pharmacol Toxicol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429517305964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429517305964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T22:40:53Z","timestamp":1750286453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429517305964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":38,"alternative-id":["S0090429517305964"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2017.05.041","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Beneficial Effect of Fesoterodine, a Competitive Muscarinic Receptor Antagonist on Erectile Dysfunction in Streptozotocin-induced Diabetic Rats","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2017.05.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}